Investigating polypharmacy and drug burden index in hospitalised older people

Internal Medicine Journal

Volumn 43, Issue 8, 2013, Pages 912-918

  Best, O ^a   Gnjidic, D ^a,b,c,d   Hilmer, S N ^b,d   Naganathan, V ^b,c   McLachlan, Andrew J ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Department of Microbiology and Infectious Diseases   (Australia)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Adverse drug reaction; Aged; Delirium; Drug burden index; Fall; Polypharmacy

Indexed keywords

ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OPIATE AGONIST; SEDATIVE AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; HYPNOTIC SEDATIVE AGENT;

AGED; ARTICLE; CHARLSON COMORBIDITY INDEX; CONTROLLED STUDY; DELIRIUM; DRUG BURDEN INDEX; FEMALE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OUTCOME ASSESSMENT; PHARMACOLOGICAL PARAMETERS; POLYPHARMACY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNIVERSITY HOSPITAL; VERY ELDERLY; AGE; AUSTRALIA; CHEMICALLY INDUCED; COHORT ANALYSIS; TRENDS; ADVERSE DRUG REACTION; CHEMICALLY INDUCED DISORDER; FALLING;

AGE FACTORS; AGED; AGED, 80 AND OVER; CHOLINERGIC ANTAGONISTS; COHORT STUDIES; DELIRIUM; FEMALE; HOSPITALIZATION; HUMANS; HYPNOTICS AND SEDATIVES; MALE; NEW SOUTH WALES; POLYPHARMACY; RETROSPECTIVE STUDIES;

ADVERSE DRUG REACTION; AGED; DELIRIUM; DRUG BURDEN INDEX; FALL; POLYPHARMACY;

EID: 84892706799     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12203     Document Type: Article

References (45)

1. Mannesse CK, Derkx FH, de Ridder MA, Manin ’t Veld AJ, van der Cammen TJ. Contribution of adverse drug reactions to hospital admission of older patients. Age Ageing 2000; 29: 35–9.
2. Hilmer SN, Gnjidic D. The effects of polypharmacy in older adults. Clin Pharmacol Ther 2009; 85: 86–8.
3. Zhang M, Holman CDAJ, Preen DB, Brameld K. Repeat adverse drug reactions causing hospitalization in older Australians: a population-based longitudinal study 1980–2003. Br J Clin Pharmacol 2007; 63: 163–70.
4. Hanlon JT, Pieper CF, Hajjar ER, Sloane RJ, Lindblad CI, Ruby CM et al. Incidence and predictors of all and preventable adverse drug reactions in frail elderly persons after hospital stay. J Gerontol A Biol Sci Med Sci 2006; 61: 511–5.
5. Bjerrum L, Sogaard J, Hallas J, Kragstrup J. Polypharmacy: correlations with sex, age and drug regimen A prescription database study. Eur J Clin Pharmacol 1998; 54: 197–202.
6. Iyer S, Naganathan V, McLachlan AJ, Le Couteur DG. Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs Aging 2008; 25: 1021–31.
7. Taipale HT, Hartikainen S, Bell JS. A comparison of four methods to quantify the cumulative effect of taking multiple drugs with sedative properties. Am J Geriatr Pharmacother 2010; 8: 460–71.
8. Walker J, Wynne H. Review: the frequency and severity of adverse drug reactions in elderly people. Age Ageing 1994; 23: 255–9.
9. Allain H, Bentue-Ferrer D, Polard E, Akwa Y, Patat A. Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review. Drugs Aging 2005; 22: 749–65.
10. Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging 1993; 3: 335–48.
11. Ray PG, Meador KJ, Loring DW, Zamrini EW, Yang X-H, Buccafusco JJ. Central anticholinergic hypersensitivity in aging. J Geriatr Psychiatry Neurol 1992; 5: 72–7.
12. Schmader KE, Hanlon JT, Pieper CF, Sloane R, Ruby CM, Twersky J et al. Effects of geriatric evaluation and management on adverse drug reactions and suboptimal prescribing in the frail elderly. Am J Med 2004; 116: 394–401.
13. Kuchel GA. Part III: geriatric syndromes. In: Halter JB, Ouslander JG, Tinetti ME, Studenski S, High KP, Asthana S, eds. Hazzard’s Geriatric Medicine and Gerontology, 6th edn. Sydney: McGraw-Hill; 2009; 621–738.
14. Bell J, Mezrani C, Blacker N, LeBlanc T, Frank O, Alderman CP et al. Anticholinergic and sedative medicines: prescribing considerations for people with dementia. Aust Fam Physician 2012; 41: 45–9.
15. Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. Br Med J 1997; 315: 1096–9.
16. Meagher DJ. Delirium: optimising management. Br Med J 2001; 322: 144–9.
17. Flacker JM, Cummings V, Mach JR, Bettin KBS, Kiely DK, Wei J. The association of serum anticholinergic activity with delirium in elderly medical patients. Am J Geriatr Psychiatry 1998; 6: 31–41.
18. Stevens J, Corso P, Finkelstein E, Miller T. The costs of fatal and non-fatal falls among older adults. Inj Prev 2006; 12: 290–5.
19. Carroll NV, Slattum PW, Cox FM. The cost of falls among the communitydwelling elderly. J Manag Care Pharm 2005; 11: 307–16.
20. Wilson NM, Hilmer SN, March LM, Cameron ID, Lord SR, Seibel MJ et al. Associations between drug burden index and falls in older people in residential aged care. J Am Geriatr Soc 2011; 59: 875–80.
21. Neutel CI, Perry S, Maxwell C. Medication use and risk of falls. Pharmacoepidemiol Drug Saf 2002; 11: 97–104.
22. Liu B, Anderson G, Mittmann N, To T, Axcell T, Shear N. Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998; 351: 1303–7.
23. Kelly KD, Pickett W, Yiannakoulias N, Rowe BH, Schopflocher DP, Svenson L et al. Medication use and falls in community-dwelling older persons. Age Ageing 2003; 32: 503–9.
24. Gnjidic D, Hilmer SN, Blyth F, Naganathan V, Waite L, Seibel MJ et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiology 2012; 65: 989–95.
25. Han L, Agostini JV, Allore HG. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc 2008; 56: 2203–10.
26. Hilmer SN, Mager DE, Simonsick EM, Cao Y, Ling SM, Windham BG et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med 2007; 167: 781–7.
27. Gnjidic D, Cumming RG, Le Couteur DG, Handelsman DJ, Naganathan V, Abernethy DR et al. Drug burden index and physical function in older Australian men. Br J Clin Pharmacol 2009; 68: 97–105.
28. Aparasu RR, Jano E, Johnson ML, Chen H. Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients. Am J Geriatr Pharmacother 2008; 6: 198–204.
29. Klarin I, Wimo A, Fastbom J. The association of inappropriate drug use with hospitalisation and mortality. Drugs Aging 2005; 22: 69–82.
30. Cao YJ, Mager DE, Simonsick EM, Hilmer SN, Ling SM, Windham BG et al. Physical and cognitive performance and burden of anticholinergics, sedatives, and ACE inhibitors in older women. Clin Pharmacol Ther 2007; 83: 422–9.
31. Hilmer SN, Mager DE, Simonsick EM, Ling SM, Windham BG, Harris TB et al. Drug burden index score and functional decline in older people. Am J Med 2009; 122: 1142–9.
32. Gnjidic D, Bell JS, Hilmer SN, Lonnroos E, Sulkava R, Hartikainen S. Drug burden index associated with function in community-dwelling older people in Finland: a cross-sectional study. Ann Med 2012; 44: 458–67.
33. Gnjidic D, Le Couteur DG, Abernethy DR, Hilmer SN. Drug burden index and Beers criteria: impact on functional outcomes in older people living in self-care retirement villages. J Clin Pharm 2012; 52: 258–65.
34. Gnjidic D, Hilmer SN, Blyth F, Naganathan V, Cumming RG, Handelsman D et al. High risk prescribing and incidence of frailty among older community-dwelling men. Clin Pharmacol Ther 2012; 91: 521–8.
35. Lowry E, Woodman R, Soiza R, Hilmer S, Mangoni A. Drug burden index, physical function, and adverse outcomes in older hospitalized patients. J Clin Pharmacol 2012; 52: 1584–91.
36. Lonnroos E, Gnjidic D, Hilmer S, Bell JS, Kautiainen H, Sulkava R et al. Drug burden index and hospitalization among community-dwelling older people. Drugs Aging 2012; 29: 395–404.
37. Steinman MA, Seth Landefeld C, Rosenthal GE, Berthenthal D, Sen S, Kaboli PJ. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc 2006; 54: 1516–23.
38. Donohoo E. MIMS Annual 2011. Sydney, Australia: CMP Medica; 2011.
39. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol 2003; 56: 221–9.
40. Hall W, Ramachandran R, Narayan S, Jani A, Vijayakumar S. An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer 2004; 4: 1–8.
41. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245–51.
42. Nishtala PS, Hilmer SN, McLachlan AJ, Hannan PJ, Chen TF. Impact of residential medication management reviews on drug burden index in aged-care homes: a retrospective analysis. Drugs Aging 2009; 26: 677–86.
43. Betteridge TM, Frampton CM, Jardine DL. Polypharmacy –we make it worse! A cross-sectional study from an acute admissions unit. Intern Med J 2012; 42: 208–11.
44. Saad M, Harisingani R, Katinas L. Impact of geriatric consultation on the number of medications in hospitalized older patients. Consult Pharm 2012; 27: 42–8.
45. Nguyen J, Fouts M, Kotabe S, Lo E. Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. Am J Geriatr Pharmacother 2006; 4: 36–41.